Editorial
Patient accrual into chemotherapy trials in non-small cell lung cancer
| The first 150 words of the full text of this article appear below. |
In this edition of Thorax Spiro and colleagues1 report their perceived failure to recruit patients to the Big Lung trial (BLT). It is appropriate to consider why only 9% of eligible patients entered the trial and what impact this has on this important study.
BLT addresses the role of cisplatin-based combination chemotherapy in
non-small cell lung cancer (NSCLC). This is not a trivial regime in a
patient group with a median age of 67 years, many of whom will have
major vascular co-morbidities. That fewer than one sixth of patients
were deemed ineligible for these reasons is surprising. It is also
noteworthy that 12% of patients had elective chemotherapy
presumably
all with inoperable disease since there is no current evidence to
justify routine postoperative adjuvant therapy. It is disappointing,
but hardly surprising in the current UK research environment with its
dependence on the pharmaceutical industry, that 13% of patients were
treated
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
